Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI 302 in Advanced Hepatocellular Carcinoma
NCT03908840Phase 1Unknown
- Sponsor
- Therapure Biopharma Inc.
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TBI-302 in hepatocellular carcinoma (HCC), sponsored by Therapure Biopharma Inc. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 1 year. Status: unknown.
02
Drugs
TBI-302
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03908840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03908840.